Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zezhong Liu

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Viruses|March 26, 2022
A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of ConcernLixiao Xing, Xinfeng Xu, Wei Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 10, 2023
A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primatesZezhong Liu, Jie Zhou, Xinling Wang, et al.
Advanced Healthcare Materials|November 14, 2023
Intranasal G5-BGG/pDNA Vaccine Elicits Protective Systemic and Mucosal Immunity against SARS-CoV-2 by Transfecting Mucosal Dendritic CellsHan Zhang, Zezhong Liu, Hongye Lihe, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 16, 2026
Rational Design of Broad-Spectrum Anti-Enteroviral Molecular Glues Targeting Enteroviral RNAi SuppressorsYuan Fang, Xiong Xie, Huidi Fan, et al.
Acta Pharmaceutica Sinica. B|August 9, 2021
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseasesJie Zhou, Wei Xu, Zezhong Liu, et al.
Cell Reports. Medicine|March 1, 2024
Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBDZezhong Liu, Jie Zhou, Weijie Wang, et al.
Signal Transduction and Targeted Therapy|November 28, 2020
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody responseZezhong Liu, Wei Xu, Shuai Xia, et al.
Viruses|March 26, 2022
Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta VariantNaru Zhang, Qianting Ji, Zezhong Liu, et al.
Cell Research|February 25, 2022
A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variantZezhong Liu, Jasper Fuk-Woo Chan, Jie Zhou, et al.
Medcomm|July 8, 2025
Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron SubvariantsGuangxu Zhang, Qian Wang, Kai Ji, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Viruses|March 26, 2022
A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of ConcernLixiao Xing, Xinfeng Xu, Wei Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 10, 2023
A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primatesZezhong Liu, Jie Zhou, Xinling Wang, et al.
Advanced Healthcare Materials|November 14, 2023
Intranasal G5-BGG/pDNA Vaccine Elicits Protective Systemic and Mucosal Immunity against SARS-CoV-2 by Transfecting Mucosal Dendritic CellsHan Zhang, Zezhong Liu, Hongye Lihe, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 16, 2026
Rational Design of Broad-Spectrum Anti-Enteroviral Molecular Glues Targeting Enteroviral RNAi SuppressorsYuan Fang, Xiong Xie, Huidi Fan, et al.
Acta Pharmaceutica Sinica. B|August 9, 2021
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseasesJie Zhou, Wei Xu, Zezhong Liu, et al.
Cell Reports. Medicine|March 1, 2024
Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBDZezhong Liu, Jie Zhou, Weijie Wang, et al.
Signal Transduction and Targeted Therapy|November 28, 2020
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody responseZezhong Liu, Wei Xu, Shuai Xia, et al.
Viruses|March 26, 2022
Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta VariantNaru Zhang, Qianting Ji, Zezhong Liu, et al.
Cell Research|February 25, 2022
A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variantZezhong Liu, Jasper Fuk-Woo Chan, Jie Zhou, et al.
Medcomm|July 8, 2025
Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron SubvariantsGuangxu Zhang, Qian Wang, Kai Ji, et al.
Pageof 5